content_image/286566.jpg
## Hope for Patients With Infectious Diseases 

A s a researcher working on hepatitis C clinical trials around the world, Brian Woodfall, M.D., is only too aware of the challenges patients face. Many endure yearlong drug treatments only to have to undergo a liver transplant or even die from complications related to the blood-borne virus. 

 “Many people don’t tolerate the current drugs very well and feel sick,” says Woodfall, Vice President of Global Clinical Development for Tibotec Pharmaceuticals. “And at the end of the treatment, so many people aren’t cured.” The current standard treatment may be successful in less than  50  percent of patients who have the most prevalent form of hepatitis C, and there are no alternative medicines for those who don’t respond. 

About 170  million people worldwide are infected with hepatitis C, with 3  to 4 million new cases each year, according to the World Health Organization. It is a common cause of cirrhosis of the liver, liver cancer and liver transplants worldwide. 

## INNOVATIVE TREATMENTS AIM TO CURE MORE PATIENTS 

To meet this critical need, Tibotec Pharmaceuticals is developing two new treatments for hepatitis C. The drugs, telaprevir and TMC 435 *, have the potential to cure significantly more people than currently available therapies and to halve patients’ treatment time, from 12 months to six. Telaprevir was named one of the top 10  medical innovations for  2011  by the Cleveland Clinic. It is now undergoing 

## PHARMACEUTICALS 

review by the U.S. Food and Drug Admin- istration and the European Medicines Agency. TMC 435  is being evaluated globally in several large Phase III trials. 

“These drugs will potentially decrease patients’ time away from work and family, and get them back to improved health faster,” Woodfall says. “Our research is driven by an intense commitment to save lives and improve patients’ health on a day-to-day basis.” 

## R&D EXPANDS IN INFECTIOUS DISEASES 

The hepatitis C medicines are among the treatments that the Infectious Diseases and Vaccines Therapeutic Area is developing to address high unmet medical needs globally. Already a world leader in HIV medicines, the franchise is developing new treatments for tuberculosis (TB) and HIV, and has part- nered with Crucell N.V. to develop an influenza treatment and vaccine. In February 2011 , Johnson & Johnson completed its tender offer for Crucell, which develops vaccines against infectious diseases world- wide. As a result, Crucell will now operate as the center for vaccines within the Pharmaceuticals group. 

“We are developing more effective treatments for infectious diseases to improve the lives of millions of people around the world,” says Paul Stoffels, M.D., Worldwide Chairman, Pharmaceuticals. 

 “In addition to our growing research and 

<img src='content_image/286566.jpg'>

development in infectious diseases,” he adds, “we will have a greater impact on improving human health globally with our expansion into prevention as we build our vaccines pipeline, particularly in emerging markets.” 

## BREAKTHROUGH TREATMENTS 

One of the world’s oldest and most deadly infectious diseases, tuberculosis kills 1.8  million people a year. Company researchers’ work in TB has been ground- breaking, and for the first time in more than 40  years, a new class of drugs potentially effective against TB has been 

